ME - 23andMe Holding Co.

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
(650) 938-6300
https://www.23andme.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo769

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Ms. Anne WojcickiCo-Founder, CEO, Pres & Director59.28kN/DN/D
Ms. Kathy L. Hibbs Esq., J.D.Chief Admin. Officer and Sec.567.2k340.28k1964
Dr. Kenneth J. Hillan Ch.B., M.B.Chief Therapeutics Officer582.2kN/D1961
Mr. Joseph SelsavageInterim CFO & Accounting OfficerN/DN/D1963
Dr. Joseph R. Arron M.D., Ph.D.Chief Scientific OfficerN/DN/DN/D
Ms. Jacquie Cooke Haggarty J.D.Gen. Counsel & Privacy OfficerN/DN/DN/D
Ms. Katie WatsonVP of CommunicationsN/DN/D1978
Mr. Jonathan WardChief Marketing OfficerN/DN/DN/D
Mr. Reza Afkhami M.B.A.Chief Corp. Devel. OfficerN/DN/DN/D
Ms. Savita PillaiVP of PeopleN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications; and Lemonaid telehealth platform, patients can access affiliated licensed healthcare professionals for medical consultation and treatment for several common conditions, as well as research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline plc to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Gestión corporativa

La calificación ISS Governance QuickScore de 23andMe Holding Co. a partir del 1 de junio de 2023 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 10; Compensación: 10.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.